Alzamend Neuro (ALZN) Competitors $2.27 -0.11 (-4.62%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$2.28 +0.02 (+0.66%) As of 08/6/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. SCYX, TPST, JATT, MIRA, NNVC, BDRX, TENX, LSTA, QTTB, and CASIShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include SCYNEXIS (SCYX), Tempest Therapeutics (TPST), JATT Acquisition (JATT), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Biodexa Pharmaceuticals (BDRX), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Q32 Bio (QTTB), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors SCYNEXIS Tempest Therapeutics JATT Acquisition MIRA Pharmaceuticals NanoViricides Biodexa Pharmaceuticals Tenax Therapeutics Lisata Therapeutics Q32 Bio CASI Pharmaceuticals Alzamend Neuro (NASDAQ:ALZN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Do institutionals & insiders believe in ALZN or SCYX? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by company insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer ALZN or SCYX? In the previous week, Alzamend Neuro had 4 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for Alzamend Neuro and 0 mentions for SCYNEXIS. Alzamend Neuro's average media sentiment score of 0.07 beat SCYNEXIS's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media. Company Overall Sentiment Alzamend Neuro Neutral SCYNEXIS Neutral Do analysts prefer ALZN or SCYX? Alzamend Neuro currently has a consensus price target of $180.00, indicating a potential upside of 7,829.52%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, ALZN or SCYX? Alzamend Neuro has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Which has stronger valuation and earnings, ALZN or SCYX? Alzamend Neuro has higher earnings, but lower revenue than SCYNEXIS. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$4.51MN/AN/ASCYNEXIS$3.75M7.62-$21.29M-$0.56-1.31 Is ALZN or SCYX more profitable? Alzamend Neuro has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat Alzamend Neuro's return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A -181.34% -116.84% SCYNEXIS -1,030.04%-53.47%-32.86% SummaryAlzamend Neuro beats SCYNEXIS on 8 of the 13 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.89M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.13%P/E RatioN/A16.5729.3723.99Price / SalesN/A314.79444.1896.63Price / CashN/A42.1735.8458.51Price / Book0.467.818.085.58Net Income-$4.51M-$54.52M$3.26B$265.35M7 Day Performance0.89%0.41%0.45%-0.07%1 Month Performance-21.18%9.93%4.83%1.76%1 Year Performance-87.93%15.18%30.28%25.39% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.9617 of 5 stars$2.27-4.6%$180.00+7,829.5%-89.0%$6.89MN/A0.004SCYXSCYNEXIS0.4243 of 5 stars$0.70-0.2%N/A-62.3%$27.12M$2.63M-1.2460TPSTTempest Therapeutics2.182 of 5 stars$7.39-1.0%$30.00+306.2%-64.5%$26.99MN/A-0.4120Negative NewsUpcoming EarningsJATTJATT AcquisitionN/A$1.50+7.1%N/A-57.3%$25.88MN/A0.003High Trading VolumeMIRAMIRA Pharmaceuticals2.2337 of 5 stars$1.52-3.5%$17.00+1,022.1%-37.3%$25.63MN/A-2.972Upcoming EarningsNNVCNanoViricides0.497 of 5 stars$1.59-0.3%N/A-22.8%$25.47MN/A-2.2020BDRXBiodexa Pharmaceuticals0.0813 of 5 stars$6.95-0.4%N/AN/A$25.24M$470K0.0020News CoverageShort Interest ↑TENXTenax Therapeutics1.3201 of 5 stars$6.07-1.8%$17.50+188.3%+62.5%$25.18MN/A-2.459Upcoming EarningsLSTALisata Therapeutics2.3139 of 5 stars$2.77+7.8%$23.50+748.4%+0.7%$23.87M$1M-1.2030Positive NewsUpcoming EarningsHigh Trading VolumeQTTBQ32 Bio2.2738 of 5 stars$1.96+1.3%$12.17+522.3%-94.7%$23.85M$1.16M-0.4039News CoverageShort Interest ↑Gap DownCASICASI Pharmaceuticals3.9666 of 5 stars$1.92-1.8%$4.00+108.9%-73.7%$23.55M$31.37M-0.75180News CoverageHigh Trading Volume Related Companies and Tools Related Companies SCYNEXIS Competitors Tempest Therapeutics Competitors JATT Acquisition Competitors MIRA Pharmaceuticals Competitors NanoViricides Competitors Biodexa Pharmaceuticals Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Q32 Bio Competitors CASI Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
